TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32677997

Group type: EXPERIMENTAL
Intervention: Nociceptin in synovial fluid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nociceptin in plasma pre-procedure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nociceptin in plasma post-tourniquet deflation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of nociceptin concentration in synovial fluid vs plasma pre-procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of nociceptin concentration in synovial fluid vs plasma post-tourniquet deflation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of nociceptin concentration in females vs males
Number of subjects: 20
Study: 32678292

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32678426

Group type: EXPERIMENTAL
Intervention: Intra-abdominal hypertension (IAH)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Body mass index >25 kg/m2
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Previous history of peritoneal dialysis
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: IAH Grades III and IV
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: IAH patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Evolution of intravesical pressure (IVP)
Number of subjects: 107
Study: 32678436

Group type: EXPERIMENTAL
Intervention: 6-week blueberry-enriched diet (38 g of freeze-dried blueberries daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: acute blueberry-enriched diet serum
Number of subjects: 22

Group type: COMPARATOR
Intervention: 6-week blueberry-enriched diet serum
Number of subjects: 22
Study: 32680417

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for groups (IPTG)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 489
Study: 32680448

Group type: EXPERIMENTAL
Intervention: Mealtime Engagement Scale (18-item scale)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Providing one-on-one assistance
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Re-approaching individual to continue meal
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Rasch model
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Item Response Theory models
Number of subjects: 87
Study: 32680480

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg once daily for 12 weeks, followed by 12-week dose titration (up to 10 mg)
Number of subjects: 71
Study: 32680541

Group type: EXPERIMENTAL
Intervention: Intraovarian injection of autologous bone marrow-derived mesenchymal stem cells
Number of subjects: 2
Study: 32680942

Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neurologic manifestations
Number of subjects: 64
Study: 32681140

Group type: EXPERIMENTAL
Intervention: Low anterior resection for rectal cancer
Number of subjects: 125

Group type: COMPARATOR
Intervention: Preoperative (chemo)radiotherapy
Number of subjects: 125
Study: 32681472

Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine (120 µg at 0, 2, 6 months)
Number of subjects: 8026
Study: 32681477

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT) with Irreversible Electroporation (IRE) and FOLFIRINOX
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT) with IRE and FOLFIRINOX
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT) with either FOLFIRINOX or gemcitabine
Number of subjects: 5

Group type: COMPARATOR
Intervention: FOLFIRINOX alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Gemcitabine + IRE
Number of subjects: 5

Group type: COMPARATOR
Intervention: IRE alone
Number of subjects: 5
Study: 32681659

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline levels of C3c
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: C3c levels
Number of subjects: 33

Group type: COMPARATOR
Intervention: C3 and C3c levels
Number of subjects: 33

Group type: COMPARATOR
Intervention: C3 levels
Number of subjects: 33
Study: 32681682

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (EXP3B subgroup)
Number of subjects: 39
Study: 32681700

Group type: EXPERIMENTAL
Intervention: sST2 levels
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CST levels
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: sST2 as a predictor of in-hospital death
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CST as a predictor of in-hospital death
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: sST2 AUC for classifying non-survivors from survivors
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CST AUC for classifying non-survivors from survivors
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: NT-proBNP AUC for classifying non-survivors from survivors
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: sST2 levels ≥35 ng/mL among survivors
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Correlation of sST2 and CST levels
Number of subjects: 96
Study: 32682441

Group type: EXPERIMENTAL
Intervention: Functional, structural, and patient-reported candidate outcomes in the cross-sectional part (1 month duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional, structural, and patient-reported outcomes in the longitudinal part (36 months duration)
Number of subjects: 0
Study: 32682451

Group type: EXPERIMENTAL
Intervention: TyG index group I (lowest)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: TyG index group II
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: TyG index group III (highest)
Number of subjects: 1143
Study: 32682555

Group type: EXPERIMENTAL
Intervention: General anaesthesia with isoflurane
Number of subjects: 1002
Study: 32682670

Group type: EXPERIMENTAL
Intervention: Ataluren (a read-through agent for premature nonsense codons)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Fuchs criteria definitions
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Fuchs criteria assessment
Number of subjects: 751
Study: 32682713

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (1.5-T)
Number of subjects: 134
Study: 32682715

Group type: EXPERIMENTAL
Intervention: Reduced PALS (PALS ≤18%)
Number of subjects: 2461

Group type: COMPARATOR
Intervention: Normal PALS (PALS >18%)
Number of subjects: 2461
Study: 32682718

Group type: EXPERIMENTAL
Intervention: CMR-FT global longitudinal peak strain (GLS)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: CMR-FT
Number of subjects: 455
Study: 32682714

Group type: EXPERIMENTAL
Intervention: Severe stress B-lines (score ≥10)
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Abnormal heart rate reserve
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Abnormal coronary flow velocity reserve
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2145
Study: 32682875

Group type: EXPERIMENTAL
Intervention: Sleep medications (including benzodiazepines)
Number of subjects: 0
Study: 32683101

Group type: EXPERIMENTAL
Intervention: Replacement of LAMS with plastic stents after removal of LAMS
Number of subjects: 94

Group type: COMPARATOR
Intervention: No replacement of LAMS with plastic stents
Number of subjects: 94

Group type: COMPARATOR
Intervention: Patients with intact pancreatic ducts
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall recurrence in patients with DPDS
Number of subjects: 94
Study: 32683126

Group type: EXPERIMENTAL
Intervention: Aflac-AML regimen (anthracycline-reduced approach)
Number of subjects: 27
Study: 32683127

Group type: EXPERIMENTAL
Intervention: Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (allo-HSCT) with post-transplant cyclophosphamide (PTCy)
Number of subjects: 0
Study: 32683528

Group type: EXPERIMENTAL
Intervention: Microgravity exposure (μg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (1g)
Number of subjects: 15
Study: 32683644

Group type: EXPERIMENTAL
Intervention: IV tramadol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV tramadol 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32683763

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder
Number of subjects: 113
Study: 32684069

Group type: EXPERIMENTAL
Intervention: Motor Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32684363

Group type: EXPERIMENTAL
Intervention: Fermented dairy products (FDP) consumption
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Circulating short-chain acylcarnitines (SCA)
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Acetylcarnitine (C2)
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Fermented milk consumption
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Short-chain acylcarnitines (SCA) and acetylcarnitine (C2)
Number of subjects: 1185
Study: 32685131

Group type: EXPERIMENTAL
Intervention: Polynerve synthetic polymer nerve conduit
Number of subjects: 0
Study: 32685552

Group type: EXPERIMENTAL
Intervention: Admission hyperglycemia
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: A/C (arterial blood glucose)
Number of subjects: 277
Study: 32685766

Group type: EXPERIMENTAL
Intervention: Telehealth intervention for managing risk factors in diabetic kidney disease (STOP-DKD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for cardiovascular improvement (CITIES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study: 32686047

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2719

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2719

Group type: COMPARATOR
Intervention: High-volume centre
Number of subjects: 2719
Study: 32687189

Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC) <105 μg/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC) >273 μg/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saliva Iodine Concentration (SIC) quantiles
Number of subjects: 0
Study: 32687473

Group type: EXPERIMENTAL
Intervention: Low-cost electronic adherence monitoring combined with data-informed counseling, SMS-based support, and/or alarms
Number of subjects: 49
Study: 32687478

Group type: EXPERIMENTAL
Intervention: WeChat-based integrative family intervention (WIFI) including psychoeducation, peer support, and professional support.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WeChat-based integrative family intervention (WIFI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cost data collection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Process data collection
Number of subjects: 12
Study: 32687629

Group type: COMPARATOR
Intervention: Non-pharmacological interventions (dietary, exercise, behavioural, multi-component)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological interventions (weight loss medications, medication switching)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical interventions (gastric bypass, gastric bands, biliopancreatic diversion, vertical banded gastroplasty)
Number of subjects: 0
Study: 32687899

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA) over left PFC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA) over left PFC
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA) over right PFC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA) over right PFC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA) over right PFC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA) over right PFC
Number of subjects: 9
Study: 32687977

Group type: EXPERIMENTAL
Intervention: Endoscopic resection
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Lesion size (per mm increase)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Rectal location
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Logistic regression model based on lesion size and rectal location
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: NNT for nonrectal SMIC smaller than 4 cm
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: NNT for rectal SMIC of 4 cm or more
Number of subjects: 693
Study: 32689822

Group type: EXPERIMENTAL
Intervention: Reverse LV remodeling (≥12% decrease in LVESV)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: No LV remodeling (changes in LVEDV and LVESV <12%)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Adverse LV remodeling with compensation (≥12% increase in LVEDV only)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Adverse LV remodeling (≥12% increase in both LVESV and LVEDV)
Number of subjects: 285
Study: 32689933

Group type: EXPERIMENTAL
Intervention: Maternal characteristics (BMI, glucose tolerance, mode of delivery, ethnicity)
Number of subjects: 113
Study: 32689965

Group type: EXPERIMENTAL
Intervention: Non-fallers (NFs)
Number of subjects: 83

Group type: COMPARATOR
Intervention: One-time fallers (OFs)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Recurrent-fallers (RFs)
Number of subjects: 83
Study: 32689979

Group type: EXPERIMENTAL
Intervention: RefluxStop™ device
Number of subjects: 50
Study: 32689982

Group type: EXPERIMENTAL
Intervention: Understanding Stroke web-based decision support tool
Number of subjects: 0
Study: 32690030

Group type: EXPERIMENTAL
Intervention: Dementia patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Increasing butyrate producing bacteria and targeting malnutrition
Number of subjects: 23
Study: 32690156

Group type: EXPERIMENTAL
Intervention: Modified fat breast milk (MFBM) - Target Fortification (n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified fat breast milk (MFBM) - Higher Initial Concentration (n=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High medium triglyceride (MCT) formula (n=8)
Number of subjects: 24
Study: 32690157

Group type: EXPERIMENTAL
Intervention: Combined training three times a week for 12 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 17
Study: 32690246

Group type: EXPERIMENTAL
Intervention: Heart rate reduction intervention
Number of subjects: 45
Study: 32690505

Group type: EXPERIMENTAL
Intervention: Universal suicide risk screening using smartphone technology
Number of subjects: 137927

Group type: EXPERIMENTAL
Intervention: Measurement of mental health outcomes (depression, anxiety, alcohol and substance use disorders)
Number of subjects: 137927
Study: 32690535

Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group (patients who refused ASV or stopped treatment early)
Number of subjects: 503
Study: 32690678

Group type: EXPERIMENTAL
Intervention: Structural-neuroimaging datasets
Number of subjects: 0
Study: 32690727

Group type: EXPERIMENTAL
Intervention: Abdominal radiography (AR)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound (AUS) as an add-on test with AR
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AR and AUS
Number of subjects: 200
Study: 32690731

Group type: EXPERIMENTAL
Intervention: Serological HPA-1a typing and luminex-based multiplex assay for detection of anti-HPA-1a antibodies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPA-1a immunised pregnancies with and without signs of bleeding.
Number of subjects: 0
Study: 32690735

Group type: EXPERIMENTAL
Intervention: Antibiotherapy optimisation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic permissive strategy of antibiotic prophylaxis and treatment
Number of subjects: 0
Study: 32690786

Group type: EXPERIMENTAL
Intervention: Brain-responsive neurostimulation
Number of subjects: 230
Study: 32690797

Group type: EXPERIMENTAL
Intervention: bimagrumab 10 mg/kg IV every 4 weeks up to 2 years (104 weeks)
Number of subjects: 10
Study: 32690798

Group type: EXPERIMENTAL
Intervention: Continuous EEG monitoring (CEEG)
Number of subjects: 719
Study: 32691048

Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration (increased)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration (baseline increase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nighttime sleep duration (no change or decrease)
Number of subjects: 0
Study: 32691060

Group type: EXPERIMENTAL
Intervention: Neoantigen vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Checkpoint blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of neoantigen vaccines and checkpoint blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32691232

Group type: EXPERIMENTAL
Intervention: Endoscopic single flap tympanoplasty
Number of subjects: 104

Group type: COMPARATOR
Intervention: Endoscopic double flap tympanoplasty
Number of subjects: 104
Study: 32691242

Group type: EXPERIMENTAL
Intervention: Idarucizumab (2.5 + 2.5 g, intravenous) administered 2 hours after the last administration of dabigatran etexilate (220 mg b.i.d., oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dabigatran etexilate (220 mg b.i.d., oral) alone
Number of subjects: 12
Study: 32691879

Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 1315
Study: 32692109

Group type: EXPERIMENTAL
Intervention: Epi-PrEP (short-term, fixed-interval episodic PrEP)
Number of subjects: 54
Study: 32692282

Group type: EXPERIMENTAL
Intervention: Effortful control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 0
Study: 32692301

Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced MR angiography
Number of subjects: 59

Group type: COMPARATOR
Intervention: Duplex US
Number of subjects: 59
Study: 32692345

Group type: EXPERIMENTAL
Intervention: Ultra-Processed Foods (UPFs) consumption by vegetarians
Number of subjects: 21212

Group type: EXPERIMENTAL
Intervention: Nutritional quality of diets measured by healthy plant-based diet indices (PDI)
Number of subjects: 21212

Group type: EXPERIMENTAL
Intervention: Age at vegetarian diet initiation
Number of subjects: 21212

Group type: EXPERIMENTAL
Intervention: Duration of vegetarian diet
Number of subjects: 21212
Study: 32692356

Group type: EXPERIMENTAL
Intervention: High social support (+1 SD)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Low social support (-1 SD)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Low social support
Number of subjects: 143
Study: 32692367

Group type: EXPERIMENTAL
Intervention: 3.5 g GOS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 7 g GOS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 15 g GOS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 7 g GOS with 93 mg AA
Number of subjects: 46
Study: 32692450

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg daily for days 1-21 of 28-day cycles)
Number of subjects: 21
Study: 32692715

Group type: EXPERIMENTAL
Intervention: cTOI/pTOI-ratio
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: cTOI
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: pTOI
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Arterial oxygen saturation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Body temperature
Number of subjects: 87
Study: 32692850

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 12
Study: 32693406

Group type: EXPERIMENTAL
Intervention: Undetectable measurable residual disease (MRD) in patients with standard- or high-risk CAs
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Persistent MRD in patients with standard-risk CAs
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Persistent MRD in patients with high-risk CAs
Number of subjects: 390
Study: 32693411

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided through-the-needle biopsy (TTNB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fine needle aspiration (FNA) cytology
Number of subjects: 101
Study: 32693812

Group type: EXPERIMENTAL
Intervention: Collateral donor artery post-PCI
Number of subjects: 31

Group type: COMPARATOR
Intervention: Collateral donor artery pre-PCI
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Recanalized coronary artery post-PCI
Number of subjects: 31
Study: 32694147

Group type: EXPERIMENTAL
Intervention: Basic prediction model based on symptoms only
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Adding blood markers
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Adding stool markers
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Combining symptoms with blood and stool markers
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Triaging with symptoms, blood markers, and calprotectin
Number of subjects: 193
Study: 32694158

Group type: EXPERIMENTAL
Intervention: Injection of 300 MBq of (4S)-4-(3-[
Number of subjects: 20
Study: 32694159

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 0
Study: 32694182

Group type: EXPERIMENTAL
Intervention: Oxygenation factor
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oxygenation ratio
Number of subjects: 150
Study: 32694398

Group type: EXPERIMENTAL
Intervention: Colorimetric blood loss measurement
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gravimetric technique
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Visual technique
Number of subjects: 53
Study: 32694787

Group type: EXPERIMENTAL
Intervention: Artificial intelligence decision support system for the management of T1D
Number of subjects: 0
Study: 32694834

Group type: EXPERIMENTAL
Intervention: DNA methylation (DNAme)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: mean-DCCT HbA1c
Number of subjects: 499
Study: 32694857

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Recurrent wheeze
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Other children in the household <5 years old
Number of subjects: 277